Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)

SHE:300233 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	917.67	1,025	859.13	981.18	1,075
Cash & Short-Term Investments	917.67	1,025	859.13	981.18	1,075
Cash Growth	-10.44%	19.27%	-12.44%	-8.75%	8.56%
Accounts Receivable	696.8	794.56	803.39	684	790.05
Other Receivables	6.45	7.81	4.62	5.08	2.07
Receivables	703.25	802.37	808.01	689.08	792.12
Inventory	598.86	501.28	579.22	391.32	284.08
Prepaid Expenses	-	0.2	0.55	0.01	1.37
Other Current Assets	38.5	40.77	61.24	77.68	69.04
Total Current Assets	2,258	2,369	2,308	2,139	2,222
Property, Plant & Equipment	2,310	2,468	2,469	2,093	1,777
Long-Term Investments	183.28	147.52	141.22	143.31	129.39
Other Intangible Assets	513.51	547.29	452.2	449.75	494.35
Long-Term Deferred Tax Assets	63.94	69.77	51.96	30.71	40.93
Long-Term Deferred Charges	252.96	310.89	369.59	329.72	286.79
Other Long-Term Assets	23.5	3.51	34.42	89.77	49.8
Total Assets	5,605	5,916	5,826	5,275	5,000
Accounts Payable	552.56	824	726.05	515.31	299.63
Accrued Expenses	355.9	402.32	394.98	362.19	400.69
Short-Term Debt	55.04	94	212.89	223	154
Current Portion of Long-Term Debt	101.52	109.24	163.2	155.45	-
Current Portion of Leases	0.13	0.72	1.11	2.37	-
Current Income Taxes Payable	21.53	24.85	18.84	18.72	18.83
Current Unearned Revenue	50.94	32.74	44.67	54.47	35.03
Other Current Liabilities	93.35	112.47	139.2	84.94	240.73
Total Current Liabilities	1,231	1,600	1,701	1,416	1,149
Long-Term Debt	351.99	346.7	271.69	208.29	255.39
Long-Term Leases	6.88	3.46	2.02	63.52	-
Long-Term Unearned Revenue	53.88	61.6	66	54.81	51.41
Long-Term Deferred Tax Liabilities	129.1	122.94	126.21	92.66	77.11
Total Liabilities	1,773	2,135	2,167	1,836	1,533
Common Stock	383.87	383.87	387.41	387.41	391.55
Additional Paid-In Capital	2,328	2,328	2,397	2,404	2,474
Retained Earnings	1,051	967.95	850.41	653.34	622.84
Treasury Stock	-55.01	-	-56.94	-80.01	-73.55
Comprehensive Income & Other	59.49	34.62	29.33	29.44	23.45
Total Common Equity	3,767	3,714	3,607	3,394	3,438
Minority Interest	65.17	66.93	51.87	44.96	29.32
Shareholders' Equity	3,832	3,781	3,659	3,439	3,467
Total Liabilities & Equity	5,605	5,916	5,826	5,275	5,000
Total Debt	515.56	554.12	650.91	652.62	409.39
Net Cash (Debt)	402.11	470.54	208.22	328.55	665.85
Net Cash Growth	-14.54%	125.98%	-36.62%	-50.66%	80.04%
Net Cash Per Share	1.06	1.21	0.54	0.85	1.72
Filing Date Shares Outstanding	379.33	383.87	383.1	383.87	387.41
Total Common Shares Outstanding	379.33	383.87	383.1	383.87	387.41
Working Capital	1,027	768.95	607.21	722.83	1,073
Book Value Per Share	9.93	9.68	9.42	8.84	8.87
Tangible Book Value	3,253	3,167	3,155	2,945	2,944
Tangible Book Value Per Share	8.58	8.25	8.24	7.67	7.60
Buildings	1,424	1,406	1,356	1,021	946.46
Machinery	2,414	2,289	2,152	1,671	1,388
Construction In Progress	73.33	148.97	121.31	332.32	300.44

Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.